The orphan drug launch, reconsidered
from The Refill, by MM+M Hosted by Marc Iskowitz, Charlie Gayer
Charlie Gayer, chief commercial officer for BioCryst Pharmaceuticals, talks about how his company, which recently launched an oral medicine into a crowded category, used analytics to rethink the rare-disease drug launch. Is your team still treating AI like a side experiment while competitors use it to win? Cut through the buzzword fatigue. On November 12th, join hundreds of top marketers in New York City for AI Deciphered, presented by Campaign, MM+M, and PRWeek. Get real-world playbooks from leaders like Reddit’s Rob Gaige and Yahoo’s Matt Sanchez across dedicated tracks built for daily execution. aidecipheredsummit.com. Check us out at: mmm-online.com Follow us: YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here. for information about our collection and use of personal data for advertising.
Embed this episode
What this episode covers
Charlie Gayer, chief commercial officer for BioCryst Pharmaceuticals, talks about how his company, which recently launched an oral medicine into a crowded category, used analytics to rethink the rare-disease drug launch.
No transcript yet.